OM1 Secures $21 Million in Series B Financing

Health outcomes and technology company OM1 raised a Series B financing round of $21 million led by Polaris Partners, with participation from existing investors General Catalyst and 7wire Ventures.

Using standardized health information and artificial intelligence technology, OM1 is designed to gather, synthesize, and leverage big clinical data and registries to help customers understand, compare, and predict health outcomes. According to the company, customers use the OMView™ RA system to access real-time comparative treatment outcomes across major biologics and biosimilars in rheumatoid arthritis, providing invaluable insights and evidence for decision-making.

OM1 plans to use the funding to continue the buildout of its intelligent, data-driven solutions.